A new review proposes a closed-loop precision oncology framework that combines longitudinal liquid biopsy, vascularized organoids, and explainable AI to track tumor evolution and anticipate treatment resistance in real time. The paper argues this integrated approach could move clinicians beyond static biopsy-based decisions by linking dynamic multi-omics monitoring, functional drug testing, and interpretable prediction into an iterative care cycle.

Why It Matters To Your Practice

• Static molecular snapshots can miss evolving resistance, especially in malignant neoplasm care where tumor heterogeneity changes under treatment pressure.

• Liquid biopsy may allow serial monitoring, while organoids and organ-on-chip models can test therapies in a more physiologic tumor microenvironment.

• Explainable AI could make response predictions more transparent than black-box models, potentially improving clinician trust and adoption.

Clinical Implications

• Potential workflow: use dynamic monitoring data to flag emerging resistance, validate options in patient-derived organoid platforms, then apply XAI to support treatment selection.

• Organoid systems that incorporate vascular, immune, and stromal features may better model oxygen gradients, shear stress, and drug response than conventional cultures.

• XAI methods highlighted in the review include feature perturbation, knowledge graph embedding, and dynamic Bayesian networks to clarify why a therapy is recommended.

Insights

• The core advance is not a single tool but an iterative loop: patient data inform lab models, lab findings inform AI predictions, and real-world outcomes refine the system.

• The review points to enabling technologies such as CRISPR screening, multimodal data integration, 3D bioprinting, and federated learning.

• Key barriers remain: multi-scale data integration, reproducible vascularization, standardized quality control, and regulatory expectations for transparent AI.

The Bottom Line

• This is a roadmap, not a practice-changing trial, but it frames how adaptive oncology could become more responsive to resistance as it emerges.

• For clinicians, the near-term value is in understanding how dynamic biomarkers, advanced ex vivo models, and interpretable AI may converge into future decision support.